Loading company…
Spica Therapeutics develops therapies targeting macrophage subsets in oncology and other diseases.
Founded in 2024 and based in Aarhus, Denmark, Spica Therapeutics develops therapies for oncology, fibroinflammatory, and autoimmune diseases using macrophage fingerprinting technology. Its programs target oncology and fibroinflammatory conditions. In June 2025, it raised EUR 10 million in seed funding co-led by Flanders Future Tech and Bioqube Ventures, with participation from Qbic Fund.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in